News

AACI is pleased to announce that Gilead and Novartis have joined its Corporate Roundtable and Medidata and Paradigm Health have become Tech Gold members in 2026.

New AACI Coporate Roundtable Members

Gilead and Kite Oncology are working to transform how cancer is treated with next-generation therapies, combinations, and technologies to deliver improved outcomes for people with cancer. Gilead is redefining cancer research by accelerating development of therapies and potential cures.

Novartis works to reimagine medicine to improve and extend people’s lives so that patients, health care professionals, and societies are empowered in the face of serious disease. The company's medicines reach nearly 300 million people worldwide.

New AACI Tech Gold Members

The Medidata platform connects patients, sites, sponsors, and CROs in a unified, secure, and scalable cloud environment to bring life-changing treatments to those who need them most. 

Paradigm Health is rebuilding the clinical research ecosystem by creating a platform that enables equitable access to trials for all patients, while enhancing trial efficiency and reducing the barriers to participation for health care providers. 

​The AACI Corporate Roundtable provides a forum for AACI cancer centers to address topics of mutual interest with their pharmaceutical industry colleagues. Tech Gold was launched in 2024 as a new membership category for technology companies whose products and services benefit cancer centers. This membership allows these companies to exchange ideas with AACI cancer centers and imagine new possibilities for enhancing oncology through technology. By building important relationships with AACI cancer centers, Corporate Roundtable and Tech Gold members have the potential to accelerate progress against cancer, benefiting patients and their families.

For more information about Corporate Roundtable and Tech Gold membership, please contact AACI Development Manager Chelsea Borries.